Vaara ST, Pettilä V, Reinikainen M, Kaukonen KM. Finnish Intensive Care Consortium. Population-based incidence, mortality and quality of life in critically ill patients treated with renal replacement therapy: a nationwide retrospective cohort study in Finnish intensive care units. Crit Care. 2012;16(1):R13.
Article PubMed PubMed Central Google Scholar
Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care. 2005;9(6):R700–9.
Article PubMed PubMed Central Google Scholar
Hoff BM, Maker JH, Dager WE, Heintz BH. Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update. Ann Pharmacother. 2020;54(1):43–55.
Pistolesi V, Morabito S, Di Mario F, Regolisti G, Cantarelli C, Fiaccadori E. A guide to understanding Antimicrobial Drug Dosing in critically ill patients on renal replacement therapy. Antimicrob Agents Chemother. 2019;63(8):e00583–19.
Article CAS PubMed PubMed Central Google Scholar
Jang SM, Lewis SJ, Mueller BA. Harmonizing antibiotic regimens with renal replacement therapy. Expert Rev Anti Infect Ther. 2020;18(9):887–95.
Article CAS PubMed Google Scholar
Heung M, Yessayan L. Renal replacement therapy in Acute kidney Injury: controversies and Consensus. Crit Care Clin. 2017;33(2):365–78.
Zaman T, Moore K, Jellerson J, Chahal Y, Schumacher J, Dalessandri-Silva C, et al. Extension of Tablo TrEatmeNt Duration (XTEND) study: successful 24 h prolonged therapy with Tablo in critical patients. BMC Nephrol. 2022;23(1):338.
Article CAS PubMed PubMed Central Google Scholar
Carlier M, Taccone FS, Beumier M, Seyler L, Cotton F, Jacobs F, Roberts JA. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy. Int J Antimicrob Agents. 2015;46(4):413–9.
Article CAS PubMed Google Scholar
Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2016;56(10):1277–87.
Article CAS PubMed Google Scholar
Chaijamorn W, Charoensareerat T, Srisawat N, Pattharachayakul S, Boonpeng A. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study. J Intensive Care. 2018;6:61.
Article PubMed PubMed Central Google Scholar
Jang SM, Gharibian KN, Lewis SJ, Fissell WH, Tolwani AJ, Mueller BA. A Monte Carlo simulation approach for β-lactam dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2018;58:1254–65.
Article CAS PubMed Google Scholar
Sember AM, LoFaso ME, Lewis SJ. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy. J Crit Care. 2022;69:154011.
Article CAS PubMed Google Scholar
Bagshaw SM, Wald R, Adhikari NKJ, Bellomo R, da Costa BR, Dreyfuss D, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383(3):240–51.
Article CAS PubMed Google Scholar
Allaouchiche B, Breilh D, Jaumain H, Gaillard B, Renard S, Saux MC. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 1997;41(11):2424–7.
Article CAS PubMed PubMed Central Google Scholar
Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2001;45(11):3148–55.
Article CAS PubMed PubMed Central Google Scholar
Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther. 2005;27(5):599–608.
Article CAS PubMed Google Scholar
Philpott CD, Droege CA, Droege ME, Healy DP, Courter JD, Ernst NE, et al. Pharmacokinetics and pharmacodynamics of extended-infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study. Pharmacotherapy. 2019;39(11):1066–76.
Article CAS PubMed Google Scholar
Mariat C, Venet C, Jehl F, Mwewa S, Lazarevic V, Diconne E, Fonsale N, Carricajo A, Guyomarc’h S, Vermesch R, Aubert G, Bidault R, Bertrand JC, Zeni F. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care. 2006;10(1):R26.
Article PubMed PubMed Central Google Scholar
König C, Braune S, Roberts JA, Nierhaus A, Steinmetz OM, Baehr M, Frey OR, Langebrake C, Kluge S. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis. J Antimicrob Chemother. 2017;72(5):1433–40.
Isla A, Gascon AR, Maynar J, Arzuaga A, Sanchez-Izquierdo JA, Pedraz JL. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy. 2007;53(3):194–201.
Article CAS PubMed Google Scholar
Kinowski JM, de la Coussaye JE, Bressolle F, Fabre D, Saissi G, Bouvet O, et al. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob Agents Chemother. 1993;37(3):464–73.
Article CAS PubMed PubMed Central Google Scholar
Afshartous D, Bauer SR, Connor MJ, Aduroja OA, Amde M, Salem C, et al. Pharmacokinetics and pharmacodynamics of meropenem and imipenem in critically ill patients treated with continuous venovenous hemodialysis. Am J Kidney Dis. 2014;63(1):170–1.
Article CAS PubMed Google Scholar
Boucher BA, Hudson JQ, Hill DM, Swanson JM, Wood GC, Laizure SC, et al. Pharmacokinetics of imipenem/cilastatin burn intensive care unit patients undergoing high-dose continuous venovenous hemofiltration. Pharmacotherapy. 2016;36(12):1229–37.
Article CAS PubMed Google Scholar
Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2005;49(6):2421–8.
Article CAS PubMed PubMed Central Google Scholar
Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis. 1993;21(2):172–9.
Article CAS PubMed Google Scholar
Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ASAIO J. 1997;43(1):84–8.
Vos MC, Vincent HH, Yzerman EP. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Intensive Care Med. 1992;18(5):282–5.
Article CAS PubMed Google Scholar
Kihara M, Ikeda Y, Shibata K, Masumori S, Ebira H, Shiratori K, et al. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. Clin Nephrol. 1994;42(3):193–7.
Primaxin [package insert]. Whitehouse Station. NJ: Merck Sharp & Dohme Corp; 2016.
Tegeder I, Bremer F, Oelkers R, Schobel H, Schüttler J, Brune K, et al. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1997;41(12):2640–5.
Article CAS PubMed PubMed Central Google Scholar
Isla A, Maynar J, Sánchez-Izquierdo JA, Gascón AR, Arzuaga A, Corral E, et al. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol. 2005;45:1294–304.
Article CAS PubMed Google Scholar
Robatel C, Decosterd LA, Biollaz J, Eckert P, Schaller MD, Buclin T. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol. 2003;43:1329–40.
Article CAS PubMed Google Scholar
Langgartner J, Vasold A, Glück T, Reng M, Kees F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med. 2008;34(6):1091–6.
Article CAS PubMed Google Scholar
Giles LJ, Jennings AC, Thompson AH, Creed G, Beale RJ, McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med. 2000;28:632–7.
留言 (0)